Most Read Articles
Roshini Claire Anthony, 28 Jan 2020

Individuals with type 2 diabetes (T2D) who are prescribed an SGLT2* inhibitor may have a reduced risk for developing gout compared with those who are prescribed a GLP-1** receptor agonist, according to a study from the US.

Jairia Dela Cruz, 27 Jan 2020
Bariatric surgery is beneficial to nondiabetic Asian patients with obesity, delivering sustained weight loss in addition to normalizing sugar levels and insulin resistance within 1–3 years of the procedure, as reported in a Singapore study.
4 days ago
Sleep disorder in nonstandard shift workers appears to contribute to more severe hypogonadal symptoms and lower testosterone levels when compared with daytime workers and nonstandard shift workers without sleep disorder, according to a study.

Tofogliflozin safe, effective for seniors with T2DM

22 Aug 2019

Tofogliflozin is safe and effective for elderly patients with type 2 diabetes mellitus (T2DM), regardless of insulin and oral antidiabetic drugs (OADs), reports a new Japan study.

Conducting a subanalysis of the J-STEP/EL* study, researchers evaluated the safety and efficacy of tofogliflozin in 1,497 elderly T2DM patients (mean age, 72.4±6.0 years; 52.4 percent female) who started the medication within the first 3 months of its launch.

A total of 271 patients reported adverse drug reactions (ADR), resulting in an incidence rate of 18.10 percent. There were 33 patients (2.20 percent) who experienced serious ADRs. Volume depletion-related ADRs were the most common (3.94 percent), followed by polyuria/pollakiuria (2.94 percent) and skin disorders (2.40 percent). The incidence rate of hypoglycaemia was 1.07 percent.

In terms of efficacy, researchers observed a significant drop in glycated haemoglobin (HbA1c) over time. From a baseline value of 7.64±1.35 percent, HbA1c decreased to 7.17±1.16 percent at the last observation. The mean change of –0.46±1.02 percent was statistically significant (p<0.001).

Efficacy of tofogliflozin did not meaningfully change according to the number of OADs. In those taking zero, one, two and ≥3 OADs, the mean change in HbA1c values from baseline were –0.34±0.91 percent, –0.42±1.06 percent, –0.56±1.03 percent and –0.50±1.07 percent, respectively (p<0.001 for all).

Similarly, insulin did not interfere with the effect of tofogliflozin, such that those taking the hormone showed a significant mean HbA1c change of –0.44±0.89 percent (p<0.001).

*Japanese Study of Tofogliflozin with Type 2 Diabetes Mellitus Patients in an Observational Study of the Elderly

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 28 Jan 2020

Individuals with type 2 diabetes (T2D) who are prescribed an SGLT2* inhibitor may have a reduced risk for developing gout compared with those who are prescribed a GLP-1** receptor agonist, according to a study from the US.

Jairia Dela Cruz, 27 Jan 2020
Bariatric surgery is beneficial to nondiabetic Asian patients with obesity, delivering sustained weight loss in addition to normalizing sugar levels and insulin resistance within 1–3 years of the procedure, as reported in a Singapore study.
4 days ago
Sleep disorder in nonstandard shift workers appears to contribute to more severe hypogonadal symptoms and lower testosterone levels when compared with daytime workers and nonstandard shift workers without sleep disorder, according to a study.